Yipinhong announced changes. The company cooperated to develop the new drug AR882 at home and abroad, but it still needs to carry out phase III clinical studies at home and abroad and be approved by the drug review department before it can be marketed for sale. It is uncertain whether it will pass the final approval, approval for marketing and marketing time of the regulatory authorities. AR882 has not yet been listed for sale, has not generated sales revenue, and will not have a significant impact on the company's recent performance. Investors are kindly requested to invest rationally and be aware of risks.

Zhitongcaijing · 04/14 12:49
Yipinhong announced changes. The company cooperated to develop the new drug AR882 at home and abroad, but it still needs to carry out phase III clinical studies at home and abroad and be approved by the drug review department before it can be marketed for sale. It is uncertain whether it will pass the final approval, approval for marketing and marketing time of the regulatory authorities. AR882 has not yet been listed for sale, has not generated sales revenue, and will not have a significant impact on the company's recent performance. Investors are kindly requested to invest rationally and be aware of risks.